Key facts
- Foment Bio’s last known valuation is $17.7M (Oct 2025).
- It has raised $730K across 1 recorded rounds; the latest was Seed Round ($543K) in May 2024.
- Foment Bio has filed 1 Form D with the SEC, most recently Mar 2025 ($543K sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Foment Bio
Funding rounds
1 roundsAbout Foment Bio
Developer of a non-viral gene therapy platform designed for the treatment of cardiometabolic dysfunction. The company's platform activates regenerative exosome production in vivo to reduce inflammation, prevent cell death, and restore microvasculature, enabling healthcare providers to target chronic disease with clinically tested, off-the-shelf therapeutics.
- Sector
- Healthcare
- HQ
- Montgomery, TX, United States
- Founded
- 2023
- Website
- fomentbio.com/
- Ownership
- Privately Held (backing)
Foment Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Foment Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Foment Bio in its N-PORT filings yet. We sweep new filings monthly.